New hope for genital eczema: drug trial targets severe itch and pain
NCT ID NCT07444801
First seen Mar 19, 2026 · Last updated Jun 12, 2026 · Updated 15 times
Summary
This study tests whether tralokinumab, an approved eczema drug, can improve moderate-to-severe atopic dermatitis in the genital area. About 30 adults will receive the drug and be monitored for 52 weeks using special skin imaging and symptom questionnaires. The goal is to see if it reduces itching, redness, and discomfort in this sensitive region.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CCIM, Institut für Entzündungsmedizin UKSH Lübeck
RECRUITINGLübeck, Schleswig-Holstein, 23538, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Department of Dermatology of the University Hospital Augsburg
RECRUITINGAugsburg, München, 86156, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.